Search / Trial NCT00001120

A Study of Patients With AIDS Syndrome

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of June 14, 2024

Completed

Keywords

Prospective Studies Sarcoma, Kaposi Herpesvirus 4, Human Acquired Immunodeficiency Syndrome Cohort Studies Risk Factors Lymphoma, Aids Related Antibodies, Viral Lymphoproliferative Disorders Viral Load Herpesvirus, Kaposi Sarcoma Associated Translocation (Genetics)

Description

AIDS-associated malignancy represents a model system for investigations of carcinogenesis. There are few human conditions in which cancer rates are of the magnitude they are in HIV infection. While studies have investigated pre-cancer markers in HIV-infected patients, they have not correlated these markers with tumor samples. This study contributes to understanding oncogenesis of HIV-associated malignancies by establishing a collection of tumors linked with pre-cancer sera and lymphocyte specimens, as well as prospective questionnaire data. At study entry, patients receive a comprehensive ...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • You may be eligible for this trial if you:
  • Are HIV-positive.
  • Have a CD4+ cell count of 200 cells/mm3 or below.
  • Are 18 years of age or older.
  • Exclusion Criteria
  • You will not be eligible for this trial if you:
  • Are not available for follow-up for at least 3 years.

Attachments

readout_NCT00001120_2024-06-14.pdf

4.5 MB

NCT00001120_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Indianapolis, Indiana, United States

Columbus, Ohio, United States

San Francisco, California, United States

Seattle, Washington, United States

New York, New York, United States

Rochester, New York, United States

Chapel Hill, North Carolina, United States

Durham, North Carolina, United States

Cleveland, Ohio, United States

Stanford, California, United States

Stanford, California, United States

Honolulu, Hawaii, United States

Baltimore, Maryland, United States

Buffalo, New York, United States

Cincinnati, Ohio, United States

Cleveland, Ohio, United States

New Orleans, Louisiana, United States

New Orleans, Louisiana, United States

New York, New York, United States

Boston, Massachusetts, United States

Menlo Park, California, United States

San Rafael, California, United States

Rochester, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0